Results 101 to 110 of about 27,075 (224)
International Journal of Cancer, Volume 159, Issue 10, Page 2562-2574, 15 November 2026.While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva +25 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 9, Page 2300-2313, 1 November 2026.With no effective drug‐based prevention strategies available for chemotherapy‐induced peripheral neuropathy (CIPN), research in neuroprotective approaches has grown. Of particular interest is mechanical compression, which may protect nerves by temporarily reducing blood flow during treatment. The authors here conducted a prospective trial in women with
Kadriye Başkurt +11 more
wiley +1 more source
, 2016 Pred kratkim je bilo v EU registrirano novo tarčno zdravilo LynparzaTM (olaparib) za zdravljenje bolnic z recidivnim seroznim karcinomom jajčnikov, jajcevodov ali primarnim peritonealnim seroznim karcinomom (PPSC), ki imajo znano mutacijo v genih BRCA1/2
Erik Škof, Mateja Krajc
core
NLRP4 drives olaparib resistance in pancreatic cancer
Olaparib has been approved as a treatment for metastatic pancreatic ductal adenocarcinoma in patients with BRCA1 (BRCA1 DNA repair associated) or BRCA2 mutations.
Xianjun Yu, Si Shi, Mingming Xiao
core +1 more source
Cancer and Hypertension: Shared Mechanisms, Treatment Interactions, and Clinical Management
Cancer Medicine, Volume 15, Issue 10, October 2026.ABSTRACT Cancer and hypertension (HTN) frequently coexist, and their relationship is increasingly recognized as a clinically relevant intersection between oncology and cardiovascular medicine. However, the extent to which this association reflects shared risk factors, common biological mechanisms, or treatment‐related effects remains incompletely ...
Peizhi Jia +5 more
wiley +1 more source
Libri Oncologici, 2022 Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with platinum-sensitive, BRCA-mutated, recurrent ovarian cancer treated at the University Hospital Center Split in the period from June 2016 to ...
Branka Petrić-Miše +4 more
doaj
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy in carefully selected ...
Wang Zhenyan, Wang Yan
wiley +1 more source
Lynparza (olaparib) : New Mmedicine for targeted therapy of ovarian cancer [PDF]
, 2018 A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib).
Krajc, Mateja, Škof, Erik
core +1 more source
MedComm, Volume 7, Issue 10, October 2026.Polyploid giant cancer cells (PGCCs) arise in response to stress and play a critical role in therapy resistance and tumor dormancy. These cells can evade conventional treatments and later contribute to cancer relapse by generating progeny through nonmitotic, amitotic mechanisms.
Silvia Guil‐Luna +3 more
wiley +1 more source
Targeting the DNA Damage Response in Cancer
MedComm, Volume 7, Issue 10, October 2026.Targeting the DNA damage response (DDR) reshapes both tumor vulnerability and antitumor immunity. DNA lesions and DDR inhibitors can promote cytosolic nucleic‐acid sensing, antigen presentation, and immune activation, but can also induce adaptive immune escape.
Yihuan Qiao +4 more
wiley +1 more source